recommend against dosing immunosuppressive therapy based on ANCA titer results alone. Increases in ANCA titers/levels are only modestly informative as an indicator of disease activity Recommendation: For patients with GPA/MPA who are receiving rituximab or cyclophosphamide, we conditionally recommend prophy laxis to prevent P jirovecii pneumonia. Prophylaxis to prevent P jirovecii pneumonia is routinely used with cyclophosphamide treatment Very low Recommendation: For patients with EGPA, we